FMP
AbCellera Biologics Inc.
ABCL
NASDAQ
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
3.63 USD
-0.27 (-7.44%)
About
ceo
Dr. Carl L.G. Hansen Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.abcellera.com
exchange
NASDAQ
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
CIK
0001703057
ISIN
CA00288U1066
CUSIP
00288U106
Address
2215 Yukon Street
Phone
604 559 9005
Country
CA
Employee
586
IPO Date
Dec 11, 2020
Key Executives
